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Tens of thousands of surgical procedures are performed 
every year in the UK to resolve symptoms of anal 
bleeding and prolapse caused by haemorrhoids.1 A 
steady stream of novel therapeutic approaches may 
promise more convenient, comfortable, and ultimately 
eﬀ ective treatment for this common complaint, but 
innovation is generally associated with increased cost 
and complexity compared with standard outpatient 
rubber band ligation (RBL). New surgical devices require 
systematic evaluation to support development of 
eﬀ ective patient pathways that make eﬃ  cient use of 
precious health-care resources.2
Haemorrhoidal artery ligation (HAL) uses Doppler 
equipped proctoscopy to pinpoint branches of the 
haemorrhoidal artery that supply blood to haemorrhoids. 
These feeding vessels are sutured to inhibit further 
bleeding, while a second stitch ﬁ rmly ﬁ xes the pile within 
the anal canal to prevent prolapse. Advocates of HAL 
suggest that it is much more eﬀ ective than standard RBL 
as a ﬁ rst-line treatment of haemorrhoids, justifying the 
increased cost and use of general or spinal anaesthesia.3,4 
To our knowledge, no randomised controlled trials have 
compared HAL with RBL until now.
In The Lancet, Steven Brown and colleagues5 present 
HubBLe, a randomised, non-blinded, multicentre, phase 3 
study comparing standard RBL versus HAL for ﬁ rst-line 
or selected second-line treatment of symptomatic 
haemorrhoids that prolapse and bleed following 
defecation (ie, grades II and III). This is a clinically relevant 
patient population that constitutes a large proportion 
of the surgical workload. Individuals with a history of 
haemorrhoid surgery or repeated outpatient treatments 
in the preceding 3 years were excluded.
Recurrence of haemorrhoids or haemorrhoidal 
symptoms at 12 months constituted the primary 
endpoint. This composite assessment was based on 
the presence of any one of the following: (1) patients 
reporting “unchanged or worse” symptoms, rather than 
“cured or improved”, during a telephone assessment, 
(2) further therapy being administered, or (3) symptoms 
suggestive of haemorrhoids being recorded in the 
medical notes and veriﬁ ed by two investigators blinded 
to treatment allocation. The study was powered to 
detect a 50% reduction in haemorrhoid recurrence 
at 12 months, from 30% with RBL to 15% with 
HAL. Secondary endpoints assessed at 6 weeks and 
12 months included symptom severity score, pain score, 
surgical complications, further treatment, and health 
state utility using EQ-5D.
Between September, 2012, and May, 2014, 372 patients 
entered the study, of whom 340 received treatment. 
Assessment of the primary outcome was possible in 
337 patients using 256 patient-reported outcomes, 
236 GP forms, and 337 consultant reports. Groups were 
generally well balanced with marginally more severe 
haemorrhoids allocated to HAL, and more previously 
treated patients allocated to RBL.
The major ﬁ nding of this study was that haemorrhoid 
recurrence at 12 months was signiﬁ cantly lower following 
HAL (48 [30%] of 161 patients) than following RBL (87 
[49%] of 176 patients). Actual recurrence rates were 
much higher than predicted, possibly reﬂ ecting use of a 
sensitive patient-reported outcome. Further analysis of the 
composite primary endpoint revealed that this treatment 
eﬀ ect was accounted for by patients receiving multiple 
RBL who were classiﬁ ed as having recurred. In our opinion, 
patients frequently require a course of RBL to achieve 
optimal symptom control, and the investigators might 
have inadvertently designated residual haemorrhoids as 
recurrences. Evaluation of patient-reported dissatisfaction 
at 12 months revealed no diﬀ erence between RBL and 
HAL (29%), suggesting that multiple RBL had similar 
eﬀ ectiveness than did HAL from the patients’ perspectives.
Surprisingly, HAL was associated with increased pain 
and a persistent reduction in EQ-5D compared with 
RBL, contrary to the widely held belief that it represents 
a painless approach to management of haemorrhoids.6 
Costs were also higher.
The HubBLe trial will undoubtedly change practice 
within the UK and other health-care systems with ﬁ nite 
resources. It is unique in directly comparing ﬁ rst-line 
haemorrhoidal interventions considered of most utility by 
colorectal surgeons and most acceptable by patients.7,8 This 
study has provided valuable information about the natural 
history of haemorrhoidal symptoms following treatment, 
and established a “course” of banding as a real, safe, and 
more cost-eﬀ ective means of alleviating prolapse and 
bleeding in the majority of patients. The National Institute 
for Health and Care Excellence (NICE) will probably wish to 
update their recommendations on HAL.9
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Aspirin is considered an aﬀ ordable and widely available, 
if only modestly eﬀ ective, thromboprophylactic for 
secondary stroke prevention. The two large randomised 
controlled trials of aspirin in acute ischaemic stroke 
reported that aspirin reduced the odds of early recurrent 
stroke at 2–4 weeks by about 12% (odds ratio [OR] 0·88, 
95% CI 0·79–0·97) and the odds of death or dependency 
at the end of follow-up by about 5% (OR 0·95, 
0·91–0·99).1 The ten trials of aspirin for long-term 
secondary prevention in patients with previous transient 
ischaemic attack (TIA) or ischaemic stroke reported that 
aspirin reduced the risk of any recurrent stroke over 
3 years by about 17% (relative risk [RR] 0·83, 95% CI 
0·72–0·96).2 However, non-randomised observational 
studies have suggested that urgent medical treatments, 
including aspirin, in acute TIA and mild ischaemic stroke 
reduce the risk of recurrent stroke by up to 80%.3
In The Lancet, Peter Rothwell and colleagues4 report 
ﬁ ndings from an analysis of the individual patient data 
from all randomised controlled trials of aspirin after 
ischaemic stroke or TIA, giving fresh insights into the 
eﬀ ect of aspirin on the timing and severity of recurrent 
stroke and challenging our understanding of the role of 
aspirin in secondary stroke prevention.
Rothwell and colleagues found that in the three trials of 
aspirin versus control in acute ischaemic stroke (n=40 531), 
the overall eﬀ ect of aspirin was indeed modest. However, 
there was signiﬁ cant heterogeneity according to baseline 
stroke severity (phet=0·014). Aspirin appeared far more 
eﬀ ective in reducing the 14 day risk of recurrent ischaemic 
stroke in patients with mild (OR 0·51, 95% CI 0·34–0·75) 
and moderate (0·65, 0·44–0·98) neurological damage 
after stroke, than for those with severe deﬁ cits (OR 1·10, 
0·77–1·58). Also, the reduction in recurrent stroke among 
patients with mild and moderate stroke was as great as 
half to two-thirds within the ﬁ rst 2–6 days.
Moreover, among the 12 trials of secondary prevention 
of stroke in 15 778 patients with TIA or ischaemic 
The beneﬁ ts of aspirin in early secondary stroke prevention 
The HubBLe study can help establish realistic patient 
expectations and provide a framework for counselling 
patients. This study has been a trend setter in selecting 
patient-reported outcomes as the primary endpoint. In 
context, patient-reported outcomes are now widely used, 
although this development is recent.10 Use of a patient-
centric qualitative endpoint is underpinned by the high-
quality health economics model applied in HubBLe.
The role of HAL, which has become widely accepted 
as a safe intervention for grade II–III haemorrhoids, will 
need re-evaluation. However, HAL might ﬁ nd a niche 
role as second-line treatment for patients who relapse 
following a course of RBL and do not wish to have 
excisional haemorrhoidectomy.
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